These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

152 related items for PubMed ID: 12449732

  • 1. Raltitrexed (Tomudex): an alternative choice in patients intolerant to 5-fluorouracil.
    Kempin S, Gutierrez J, Wilson E, Lowery C, Diasio R.
    Cancer Invest; 2002; 20(7-8):992-5. PubMed ID: 12449732
    [Abstract] [Full Text] [Related]

  • 2. Raltitrexed (Tomudex): an alternative drug for patients with colorectal cancer and 5-fluorouracil associated cardiotoxicity.
    Köhne CH, Thuss-Patience P, Friedrich M, Daniel PT, Kretzschmar A, Benter T, Bauer B, Dietz R, Dörken B.
    Br J Cancer; 1998 Mar; 77(6):973-7. PubMed ID: 9528843
    [Abstract] [Full Text] [Related]

  • 3. Open, randomized, multicenter trial of raltitrexed versus fluorouracil plus high-dose leucovorin in patients with advanced colorectal cancer. Tomudex Colorectal Cancer Study Group.
    Cocconi G, Cunningham D, Van Cutsem E, Francois E, Gustavsson B, van Hazel G, Kerr D, Possinger K, Hietschold SM.
    J Clin Oncol; 1998 Sep; 16(9):2943-52. PubMed ID: 9738562
    [Abstract] [Full Text] [Related]

  • 4. The use of raltitrexed (tomudex) in a patient with 5-fluorouracil induced myocardial ischaemia.
    Nutting C, Folkes A.
    Clin Oncol (R Coll Radiol); 1999 Sep; 11(1):66. PubMed ID: 10194593
    [No Abstract] [Full Text] [Related]

  • 5. Phase II study of raltitrexed (Tomudex) in chemotherapy-pretreated patients with advanced colorectal cancer. Tomudex Cooperative Study Group.
    Sato A, Kurihara M, Horikoshi N, Aiba K, Kikkawa N, Shirouzu K, Mitachi Y, Sakata Y, Wakui A.
    Anticancer Drugs; 1999 Sep; 10(8):741-8. PubMed ID: 10573207
    [Abstract] [Full Text] [Related]

  • 6. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed.
    Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A.
    Expert Opin Drug Saf; 2014 Jan; 13(1):113-29. PubMed ID: 24093908
    [Abstract] [Full Text] [Related]

  • 7. Final results of a randomised trial comparing 'Tomudex' (raltitrexed) with 5-fluorouracil plus leucovorin in advanced colorectal cancer. "Tomudex" Colorectal Cancer Study Group.
    Cunningham D, Zalcberg JR, Rath U, Oliver I, van Cutsem E, Svensson C, Seitz JF, Harper P, Kerr D, Perez-Manga G.
    Ann Oncol; 1996 Nov; 7(9):961-5. PubMed ID: 9006748
    [No Abstract] [Full Text] [Related]

  • 8. Raltitrexed. A review of its pharmacological properties and clinical efficacy in the management of advanced colorectal cancer.
    Gunasekara NS, Faulds D.
    Drugs; 1998 Mar; 55(3):423-35. PubMed ID: 9530547
    [Abstract] [Full Text] [Related]

  • 9. Patterns of elevation of plasma 2'-deoxyuridine, a surrogate marker of thymidylate synthase (TS) inhibition, after administration of two different schedules of 5-fluorouracil and the specific TS inhibitors raltitrexed (Tomudex) and ZD9331.
    Ford HE, Mitchell F, Cunningham D, Farrugia DC, Hill ME, Rees C, Calvert AH, Judson IR, Jackman AL.
    Clin Cancer Res; 2002 Jan; 8(1):103-9. PubMed ID: 11801545
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and tolerability of a new inhibitor of thymidylate synthase: 'Tomudex' (raltitrexed).
    Cunningham D.
    Tumori; 1997 Jan; 83(1 Suppl):S70-1. PubMed ID: 9154074
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Raltitrexed (tomudex) administration in patients failing multiple prior chemotherapy regimens in advanced colorectal cancer: a pilot study.
    Tsavaris N, Kosmas C, Vadiaka M, Kontos A, Fotia M, Angelopoulou A, Vrizidis N, Soulla M, Sougioultzis S, Koufos Ch.
    Invest New Drugs; 2002 Feb; 20(1):133-6. PubMed ID: 12003191
    [Abstract] [Full Text] [Related]

  • 14. 'Tomudex' (ZD1694): a novel thymidylate synthase inhibitor with clinical antitumour activity in a range of solid tumours. 'Tomudex' International Study Group.
    Cunningham D, Zalcberg J, Smith I, Gore M, Pazdur R, Burris H, Meropol NJ, Kennealey G, Seymour L.
    Ann Oncol; 1996 Feb; 7(2):179-82. PubMed ID: 8777175
    [Abstract] [Full Text] [Related]

  • 15. Thymidylate synthase inhibition, a dead end?
    Herrmann R.
    Eur J Cancer; 1995 Nov; 31A(12):1919-20. PubMed ID: 8562141
    [No Abstract] [Full Text] [Related]

  • 16. Raltitrexed treatment promotes systemic inflammatory reaction in patients with colorectal carcinoma.
    Osterlund P, Orpana A, Elomaa I, Repo H, Joensuu H.
    Br J Cancer; 2002 Sep 09; 87(6):591-9. PubMed ID: 12237767
    [Abstract] [Full Text] [Related]

  • 17. Raltitrexed (Tomudex) versus standard leucovorin-modulated bolus 5-fluorouracil: Results from the randomised phase III Pan-European Trial in Adjuvant Colon Cancer 01 (PETACC-1).
    Popov I, Carrato A, Sobrero A, Vincent M, Kerr D, Labianca R, Raffaele Bianco A, El-Serafi M, Bedenne L, Paillot B, Mini E, Sanches E, Welch J, Collette L, Praet M, Wils J.
    Eur J Cancer; 2008 Oct 09; 44(15):2204-11. PubMed ID: 18707870
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Clinical efficacy of 'Tomudex' (raltitrexed) in advanced colorectal cancer.
    Kerr DJ.
    Anticancer Drugs; 1997 Aug 09; 8 Suppl 2():S11-5. PubMed ID: 9376632
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.